Skip to main content
. Author manuscript; available in PMC: 2021 Jul 18.
Published in final edited form as: Nat Cell Biol. 2021 Jan 18;23(2):160–171. doi: 10.1038/s41556-020-00624-3

Extended Data Fig. 2. ALC1 loss enhances the therapeutic window of olaparib sensitivity in BRCA-mutant cells.

Extended Data Fig. 2

a, Sensitivities of the indicated cell lines to ola using CellTiter-Glo. Data are mean of 2 (hTERT-RPE1) or mean ± s.e.m. of 3 (UWB1.289, SUM149PT and DLD1) biologically independent experiments. b, Representative images (left) and quantification (right) of the clonogenic survival of ALC1-depleted DLD1 WT and BRCA2-mutant cells grown in the presence of increasing concentrations of ola. Data are mean ± s.e.m. from 3 biologically independent experiments. Source data are provided.